Alnylam Pharmaceuticals Inc
$ 289.39
-0.63%
11 Jun - close price
- Market Cap 39,745,360,000 USD
- Current Price $ 289.39
- High / Low $ 292.98 / 285.22
- Stock P/E 74.61
- Book Value 8.06
- EPS 3.99
- Next Earning Report 2026-07-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.10 %
- ROE 0.90 %
- 52 Week High 495.55
- 52 Week Low 283.10
About
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$441.31
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-02-12 | 2025-10-30 | 2025-07-31 | 2025-05-01 | 2025-02-13 | 2024-10-31 | 2024-08-01 | 2024-05-02 | 2024-02-15 | 2023-11-02 | 2023-08-03 |
| Reported EPS | 1.99 | 1.25 | 2.9 | 0.32 | -0.01 | 0.06 | -0.5 | 0.56 | -0.16 | -0.77 | 1.74 | -1.62 |
| Estimated EPS | 1.47 | 1.5 | 1.75 | 0.15 | -0.37 | -0.14 | -0.39 | -0.69 | -0.63 | -0.77 | -0.96 | -1.34 |
| Surprise | 0.52 | -0.25 | 1.15 | 0.17 | 0.36 | 0.2 | -0.11 | 1.25 | 0.47 | 0 | 2.7 | -0.28 |
| Surprise Percentage | 35.3741% | -16.6667% | 65.7143% | 113.3333% | 97.2973% | 142.8571% | -28.2051% | 181.1594% | 74.6032% | 0% | 281.25% | -20.8955% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-30 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 1.51 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ALNY
2026-06-12 08:09:11
Andra AP fonden significantly increased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 134.5% during the fourth quarter, now holding 48,540 shares valued at $19.30 million. This move is part of a broader trend of institutional investment, with other major hedge funds also adjusting their positions in the biopharmaceutical company. Analysts currently rate ALNY as a "Moderate Buy" with a consensus target price of $463.13.
2026-06-11 09:39:57
Motley Fool Asset Management LLC increased its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 38.5% in the fourth quarter, acquiring an additional 3,480 shares to a total of 12,526 shares valued at $4.98 million. Institutional investors collectively own 92.97% of the company's stock, with several major firms also adjusting their positions. Alnylam Pharmaceuticals reported strong quarterly results, with EPS of $1.99 against an $0.87 estimate and revenue of $1.17 billion, a 96.4% year-over-year increase.
2026-06-11 06:39:32
GENESIS Pharma and Alnylam Pharmaceuticals have expanded their commercial partnership to include Denmark, Finland, Norway, and Sweden, in addition to thirteen existing Southeast European markets. This collaboration aims to commercialize RNAi therapeutics for serious cardiomyopathy and rare genetic diseases. Both companies emphasize their commitment to increasing patient access to innovative therapies across Europe.
2026-06-10 15:10:30
Alnylam Pharmaceuticals (ALNY) is refocusing its growth expectations with 2030 goals and an AI partnership, despite a 25.6% year-to-date share price drop. While analysts suggest it's significantly undervalued based on earnings and cash flow, its high P/E ratio of 73.9x raises questions about current optimism. The valuation hinges on the success of AMVUTTRA and the wider TTR franchise.
2026-06-10 14:39:32
Genesis Pharma and Alnylam Pharmaceuticals have announced an expansion of their commercial partnership to introduce RNAi therapeutics to the Nordic region, including Denmark, Finland, Norway, and Sweden. This adds to the 13 markets already covered in Southeast Europe. The expansion aims to address significant unmet medical needs in these regions by commercializing a portfolio of RNAi therapeutics for serious cardiomyopathy conditions and rare genetic diseases.
2026-06-10 14:10:30
Alnylam Pharmaceuticals (ALNY) stock has shown a low correlation with the S&P 500 over the past five years, indicating its performance is driven more by its specific business developments than broad market trends. Despite its volatility, linked to its biotech pipeline, Alnylam has delivered strong annualized returns of 17.7% over five years, powered by impressive product revenue exceeding $1 billion in the latest quarter. The article suggests that while its recent rally is tempting, investors should consider Alnylam as a differentiated return engine to be sized carefully within a diversified portfolio.
